EnVena Automatic vein wall disruption, triggering the body’s natural cellular healing response to close targeted veins curing Venous Leg Ulcers
- Coordinator
- Invera Medical Limited, Ireland
- Runs
- 1 October 2022 to 30 September 2024
- Status
- Finished
- EU funding
- €2.5m
- Total cost
- €3.6m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190175560
What the project is doing
In the project's own words, from its summary on CORDIS.
Chronic venous disease is one of the most common diseases in the developed world, affecting up to 60% of adults over the age of 50. Chronic venous disease is the leading cause of Venous Leg Ulcers which are chronic open sores, usually on the inside of the leg that will not heal without specialist treatment. The total costs associated with managing venous disease patients across Europe and the US is €33.4 billion per year, representing 2.5% of total healthcare expenditure.
Most patients are treated with ineffective compression bandaging which does not treat the underlying cause and has an unacceptably high recurrence rate. These bandages are also sent to landfill with a high environmental impactEnVena is the world’s first device to mimic the body’s natural healing response to deliver an effective treatment to venous leg ulcer patients.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Invera Medical Limited | Dublin | Ireland | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI